• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

    2/5/25 9:00:00 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMRN alert in real time by email

    SAN RAFAEL, Calif., Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update.

    BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

    Dial-in Number 

    U.S. / Canada Dial-in Number: 800-715-9871

    International Dial-in Number: 646-307-1963

    Conference Call ID: 1878833

    U.S. / Canada Replay Dial-in Number: 800-770-2030

    International Replay Dial-in Number: 609-800-9909

    Playback ID: 1878833 

    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

    About BioMarin

    BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com. 

    Contacts:



    Investors

    Media

    Traci McCarty

    Marni Kottle

    BioMarin Pharmaceutical Inc.

     BioMarin Pharmaceutical Inc.

    (415) 455-7558

     (650) 374-2803

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-and-webcast-on-wednesday-february-19-2025-at-430pm-et-302368081.html

    SOURCE BioMarin Pharmaceutical Inc.

    Get the next $BMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRN

    DatePrice TargetRatingAnalyst
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    11/15/2024$95.00Outperform
    Wolfe Research
    10/30/2024Outperform → Mkt Perform
    William Blair
    10/10/2024$79.00Outperform
    Raymond James
    8/20/2024$94.00 → $110.00Mkt Perform → Outperform
    Bernstein
    5/17/2024$104.00 → $72.00Outperform → Neutral
    Robert W. Baird
    5/14/2024$113.00Outperform
    Evercore ISI
    11/15/2023$100.00Overweight
    Wells Fargo
    More analyst ratings

    $BMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Hubbard Cristin covered exercise/tax liability with 2,155 shares, decreasing direct ownership by 7% to 30,545 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:02:57 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walbert Timothy P was granted 6,650 shares, increasing direct ownership by 212% to 9,780 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:01:26 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Meier Richard A was granted 6,650 shares, increasing direct ownership by 6% to 127,426 units (SEC Form 4)

      4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

      5/22/25 5:00:00 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    SEC Filings

    See more
    • SEC Form 8-K filed by BioMarin Pharmaceutical Inc.

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/22/25 4:05:34 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-C filed by BioMarin Pharmaceutical Inc.

      SC TO-C - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      5/16/25 7:59:36 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioMarin Pharmaceutical Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/16/25 7:54:33 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care